amotrigine as treatment of Myotonia

Grete Andersen0 个研究点开始时间: 2013年10月21日最近更新: 2015年12月22日

适应症

试验速览

暂无简介。

•1 Age over 18 years, both men and women.
•2 Clinical myotoni: Myotoni that affect patient performance of activities of daily living (chewing function, handshake initiation of walking and running or to let go of objects) or patients who are treated with antimyotom medicine.
•3 Gen-verified diagnosis with either myotonia Congenita, Paramyotonia Congenita, Potassium-Aggravated myotonia and dystrophy Myotonica type 1
•4 Signed written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 24
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 12

•1 In treatment with medicines affecting the study results, estimated by the investigators. Or participated in the drug trial within 30 days prior to study start.
•2 Known intolerance or allergy to Lamotrigine.
•3 Significant renal or liver function, epilepsy, or long QT interval on the ECG.
•4 Pregnancy and breast-feeding.
•5 After the investigators discretion.
•Mexiletine treatment within 60 hours before study start and serum Mexilitin in therapeutic level will defer study start.

发起方

Grete Andersen